Search Results for: LYN

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
PRKCQ protein kinase C theta
  • Apoptotic cleavage of cellular proteins
  • Effects of PIP2 hydrolysis
  • Downstream TCR signaling
  • Inactivation, recovery and regulation of the phototransduction cascade
  • FCERI mediated NF-kB activation
  • FCERI mediated NF-kB activation
  • Netrin-1 signaling
  • G alpha (z) signalling events
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RAS processing
  • Tamoxifen
  • Staurosporine
  • Phosphonothreonine
  • Dexfosfoserine
  • Fostamatinib
  • Type I diabetes mellitus
PTK2B protein tyrosine kinase 2 beta
  • Signal regulatory protein family interactions
  • VEGFA-VEGFR2 Pathway
  • Interleukin-2 signaling
  • Leflunomide
  • Genistein
  • 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide
  • Baricitinib
  • Fostamatinib
CSK C-terminal Src kinase
  • GAB1 signalosome
  • Phosphorylation of CD3 and TCR zeta chains
  • Integrin signaling
  • PD-1 signaling
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Negative regulation of FLT3
  • Dasatinib
  • Staurosporine
  • TG-100801
  • Fostamatinib
ERBB4 erb-b2 receptor tyrosine kinase 4
  • Afatinib
  • Fostamatinib
  • Brigatinib
  • Zanubrutinib
IL2RB interleukin 2 receptor subunit beta
  • RAF/MAP kinase cascade
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-2 signaling
  • Interleukin receptor SHC signaling
  • Denileukin diftitox
  • Aldesleukin
  • Basiliximab
  • Daclizumab
PRKCD protein kinase C delta
  • Apoptotic cleavage of cellular proteins
  • Calmodulin induced events
  • Effects of PIP2 hydrolysis
  • SHC1 events in ERBB2 signaling
  • DAG and IP3 signaling
  • Role of phospholipids in phagocytosis
  • G alpha (z) signalling events
  • HuR (ELAVL1) binds and stabilizes mRNA
  • VEGFR2 mediated cell proliferation
  • CLEC7A (Dectin-1) signaling
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Tamoxifen
  • 13-Acetylphorbol
  • Ingenol mebutate
  • Fostamatinib
PTK2 protein tyrosine kinase 2
  • Apoptotic cleavage of cellular proteins
  • Regulation of actin dynamics for phagocytic cup formation
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • Signal regulatory protein family interactions
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate WASPs and WAVEs
  • RAF/MAP kinase cascade
  • MET activates PTK2 signaling
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • FCGR3A-mediated phagocytosis
  • Endostatin
  • 7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE
  • 2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE
  • Fostamatinib
TRPV4 transient receptor potential cation channel subfamily V member 4
  • TRP channels
  • Cannabidiol
  • Butamben
  • Medical Cannabis
  • Nabiximols
  • Spinal muscular atrophy (SMA), including: SMA type I (SMA1) / Werdning-Hoffman disease; SMA type II (SMA2); SMA type III (SMA3) / Kugeleberg-Welander disease; SMA type IV (SMA4); X-linked SMA 2 (SMAX2); X-linked distal SMA 3 (DSMAX); Distal SMA autosomal recessive type 4 (DSMA4); Congenital distal spinal muscular atrophy (SMAL); SMA proximal adult autosomal dominant (SMAPAD)
  • TRPV4-related skeletal dysplasias, including: Autosomal dominant brachyolmia; Spondylometaphyseal dysplasia, Kozlowski type (SMDK); Metatropic dysplasia; Spondyloepiphyseal dysplasia, Maroteaux type ; Parastremmatic dysplasia
  • TRPV4-related peripheral neuropathies, including: Congenital distal spinal muscular atrophy (CDSMA); Scapuloperoneal spinal muscle atrophy (SPSMA); Hereditary motor and sensory neuropathy type IIC (HMSN IIC)
  • Distal hereditary motor neuropathies (dHMN)
CASP7 caspase 7
  • Activation of caspases through apoptosome-mediated cleavage
  • SMAC (DIABLO) binds to IAPs
  • SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
  • Apoptotic cleavage of cellular proteins
  • SMAC, XIAP-regulated apoptotic response
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Fica
  • Emricasan
  • Incadronic acid
CD22 CD22 molecule
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • CD22 mediated BCR regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Epratuzumab
  • Inotuzumab ozogamicin
  • Moxetumomab Pasudotox
CSF2RB colony stimulating factor 2 receptor subunit beta
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF/MAP kinase cascade
  • Surfactant metabolism
  • Defective CSF2RB causes SMDP5
  • Defective CSF2RA causes SMDP4
  • Interleukin receptor SHC signaling
  • Sargramostim
  • NPI 32101
  • Resatorvid
FOLR1 folate receptor alpha
  • COPII-mediated vesicle transport
  • Cargo concentration in the ER
  • COPI-mediated anterograde transport
  • Folic acid
  • Vintafolide
  • Farletuzumab
ITPR1 inositol 1,4,5-trisphosphate receptor type 1
  • PLC beta mediated events
  • Effects of PIP2 hydrolysis
  • Elevation of cytosolic Ca2+ levels
  • DAG and IP3 signaling
  • Role of phospholipids in phagocytosis
  • FCERI mediated Ca+2 mobilization
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Ca2+ pathway
  • cGMP effects
  • Regulation of insulin secretion
  • VEGFR2 mediated cell proliferation
  • Ion homeostasis
  • Ion homeostasis
  • CLEC7A (Dectin-1) induces NFAT activation
  • FCGR3A-mediated IL10 synthesis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Caffeine
  • 1D-myo-inositol 1,4,5-trisphosphate
  • Glycerin
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
TYK2 tyrosine kinase 2
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • Other interleukin signaling
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Interleukin-20 family signaling
  • Interleukin-35 Signalling
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Interferon alpha/beta signaling
  • Regulation of IFNA signaling
  • Regulation of IFNA signaling
  • Potential therapeutics for SARS
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • Tofacitinib
  • Fostamatinib
  • Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
ACTB actin beta
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Gap junction degradation
  • Formation of annular gap junctions
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • HATs acetylate histones
  • Prefoldin mediated transfer of substrate to CCT/TriC
  • Folding of actin by CCT/TriC
  • EPHB-mediated forward signaling
  • EPH-ephrin mediated repulsion of cells
  • Adherens junctions interactions
  • Adherens junctions interactions
  • Recycling pathway of L1
  • Recycling pathway of L1
  • VEGFA-VEGFR2 Pathway
  • Interaction between L1 and Ankyrins
  • Interaction between L1 and Ankyrins
  • Cell-extracellular matrix interactions
  • B-WICH complex positively regulates rRNA expression
  • RHO GTPases activate IQGAPs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAP2K and MAPK activation
  • UCH proteinases
  • DNA Damage Recognition in GG-NER
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Clathrin-mediated endocytosis
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Quercetin
  • Phenethyl Isothiocyanate
  • Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome
CSNK2B casein kinase 2 beta
  • Synthesis of PC
  • WNT mediated activation of DVL
  • Condensation of Prometaphase Chromosomes
  • Signal transduction by L1
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
  • Receptor Mediated Mitophagy
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Regulation of PTEN stability and activity
  • ATP
  • Quercetin
CTLA4 cytotoxic T-lymphocyte associated protein 4
  • CTLA4 inhibitory signaling
  • RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
  • Ipilimumab
  • Tremelimumab
  • Type I diabetes mellitus
  • Graves' disease
  • Allograft rejection
  • Hashimoto's thyroiditis
DLG4 discs large MAGUK scaffold protein 4
  • Signaling by ERBB4
  • Trafficking of AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RHO GTPases activate CIT
  • RAF/MAP kinase cascade
  • LGI-ADAM interactions
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Guanidine
  • Guanosine-5'-Monophosphate
HNRNPK heterogeneous nuclear ribonucleoprotein K
  • SUMOylation of RNA binding proteins
  • mRNA Splicing - Major Pathway
  • Processing of Capped Intron-Containing Pre-mRNA
  • HCMV Late Events
  • Artenimol
  • Phenethyl Isothiocyanate
PRKDC protein kinase, DNA-activated, catalytic subunit
  • Cytosolic sensors of pathogen-associated DNA
  • IRF3-mediated induction of type I IFN
  • Nonhomologous End-Joining (NHEJ)
  • E3 ubiquitin ligases ubiquitinate target proteins
  • Caffeine
  • SF1126

Page 3 out of 7 pages